Current Rheumatology Reports

, 15:384

Osteopenia: Debates and Dilemmas

OSTEOPOROSIS AND METABOLIC BONE DISEASE (KG SAAG, SECTION EDITOR)

DOI: 10.1007/s11926-013-0384-5

Cite this article as:
Zhang, J., Morgan, S.L. & Saag, K.G. Curr Rheumatol Rep (2013) 15: 384. doi:10.1007/s11926-013-0384-5
Part of the following topical collections:
  1. Topical Collection on Osteoporosis and Metabolic Bone Disease

Abstract

Whether or not to use pharmacologic agents for primary prevention of fracture among elderly men and women with osteopenia is debated by clinicians. In this review we provide an update to enable better understanding and characterization of this population, including the prevalence of osteopenia, transitioning from osteopenia to osteoporosis, and clinically applicable tools for fracture risk assessment. We also emphasize the very limited evidence of the benefits and risks of anti-osteoporotic agents for this population for primary fracture prevention, and the need for future studies to guide clinical practice.

Keywords

OsteopeniaPharmacologic treatmentDebatesEpidemiologyFracture riskFRAXAdverse events

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA